The deal could be a big win for Seattle Genetics, but it doesn’t have the full support of all of Immunomedics investors. After the closing market bell on Friday, venBio Select Advisors, LLC — the beneficial owner of 9.9% of Immunomedics shares — said Immunomedics’ board of directors is “giving away its crown jewel.”
Category: Seattle Genetics
FDA puts Seattle Genetics drug trials on hold after 4 deaths
Seattle Genetics Inc said four people had died in trials testing its experimental cancer drug, prompting the U.S. Food and Drug Administration to impose a clinical hold on several early-stage studies. Six patients with acute myeloid leukemia , a type of blood cancer, have been identified with liver toxicity and four have died, the company said on Tuesday.